ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,775
0,17%
Bitcoin
59 608,01
0,82%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) Actualités

SNDX Syndax Pharmaceuticals Inc

21,70
-0,27 (-1,23%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Syndax Pharmaceuticals Inc SNDX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,27 -1,23% 21,70 00:00:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
22,11 21,50 22,33 21,86 21,97
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202413:00PRNUSSyndax to Announce First Quarter 2024 Financial Results and..
10/4/202422:05PRNUSSyndax Announces Participation at the Stifel 2024 Virtual..
08/4/202413:00PRNUSSyndax Presents Positive Pediatric Data from Pivotal..
05/4/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
28/3/202412:00PRNUSSyndax Announces Completion of Enrollment in AUGMENT-101..
26/3/202421:05PRNUSSyndax Announces FDA Priority Review of NDA for Revumenib..
18/3/202412:00PRNUSSyndax Announces Appointment of Steven Closter as Chief..
01/3/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
27/2/202423:28EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27/2/202423:21EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202422:05PRNUSSyndax Pharmaceuticals Reports Fourth Quarter and Full Year..
27/2/202422:03EDGAR2Form 8-K - Current report
26/2/202413:00PRNUSSyndax Announces Participation at Two Upcoming Investor..
20/2/202422:05PRNUSSyndax to Announce Fourth Quarter and Year-end 2023..
14/2/202418:50EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202413:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202403:44EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
01/2/202422:10PRNUSSyndax Announces Participation at Two Upcoming Investor..
05/1/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
02/1/202422:05PRNUSSyndax Announces Presentation at 42nd Annual J.P. Morgan..
02/1/202413:00PRNUSSyndax Highlights Recent Updates and Anticipated 2024..
20/12/202314:40EDGAR2Form 8-K - Current report
19/12/202322:16PRNUSSyndax Announces Closing of Public Offering of Common Stock..
15/12/202323:29EDGAR2Form 8-K - Current report
15/12/202323:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/12/202305:07PRNUSSyndax Announces Pricing of $200 Million Public Offering of..
14/12/202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/12/202322:00PRNUSSyndax Announces Proposed $150 Million Public Offering of..
12/12/202322:05EDGAR2Form 8-K - Current report
12/12/202318:00PRNUSSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial..
11/12/202313:30PRNUSSyndax Announces Positive Data for Revumenib in Patients..
11/12/202312:33BWIncyte und Syndax präsentieren bei ASH-Plenarsitzung weitere..
10/12/202323:00BWIncyte and Syndax Present Additional Data from Positive..
04/12/202313:00PRNUSSyndax to Host Investor Event to Discuss Axatilimab and..
01/12/202322:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
21/11/202315:00PRNUSSyndax Announces Data from Pivotal AUGMENT-101 Trial of..
07/11/202313:00PRNUSSyndax Announces Participation at Stifel Healthcare..
03/11/202321:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
02/11/202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:05PRNUSSyndax Pharmaceuticals Reports Third Quarter 2023 Financial..
02/11/202321:03EDGAR2Form 8-K - Current report
02/11/202314:00PRNUSSyndax Announces Results from the Pivotal AGAVE-201 Trial of..

Dernières Valeurs Consultées

NASDAQ
SNDX
Syndax Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés